Studies in companion dogs consistently demonstrate antitumor activity utilizing CPMV (MIE-201) alone or in combination with standard therapies against naturally occurring cancers. Data to date demonstrate similar effects as those observed in preclinical tumor models evaluating CPMV. These studies provide valuable proof of concept data regarding the consistency of CPMV's immune stimulation and antitumor effects across species. Additionally, insights into dosing amount and frequency, combined with immune modulating details available from samples of treated animals could help to inform and support the design of human clinical trials currently in planning stages. We are also evaluating regulatory requirements regarding canine oncology therapeutics which may provide a separate and expedited path toward the commercialization of our technology.

To learn more, please visit the Mosaic ImmunoEngineering Animal Health website.